SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
168.89
-0.83 (-0.49%)
As of 3:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close169.72
Open169.86
Bid168.79 x 900
Ask168.84 x 800
Day's Range168.76 - 170.03
52 Week Range123.73 - 177.51
Volume331,445
Avg. Volume883,554
Market Cap53.726B
Beta1.42
PE Ratio (TTM)11.57
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.05 (0.61%)
Ex-Dividend Date2018-03-08
1y Target EstN/A
Trade prices are not sourced from all markets
  • NYSE trader: Amazon, Visa and Twitter earnings are on my radar—their charts are very similar
    Yahoo Finance Video21 days ago

    NYSE trader: Amazon, Visa and Twitter earnings are on my radar—their charts are very similar

    Jonathan Corpina of Meridian Equity Partners joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest moves.

  • Nike, Spotify and Shire are the Yahoo Finance charts of the day.
    Yahoo Finance Video2 months ago

    Nike, Spotify and Shire are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Nike (NKE): Shares are down in early trade, at around .22%.  Nike was downgraded to "neutral" from "buy" with UBS saying it has a long-term bullish view on the athletic footwear and apparel maker. UBS also stated that the market has a similar view and the upbeat outlook is already priced into the stock. Spotify (SPOT): Shares up here, around 2.44%.  In new coverage, Macquarie starts the music streaming service at "outperform" saying the evolution of the mobile digital market positions Spotify for years of growth. Shire (SHPG): Shares up here, at around .75%.  The rare disease expert revealed that the FDA granted approval to make its Cinryze (SIN-RISE) drug available to children aged six and over. The drug has been approved for use by adults in the U.S. since 2008.  For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacksyesterday

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zacksyesterday

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT

    Q2 2018 Shire PLC Earnings Call

  • Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
    Zacks13 days ago

    Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2

    During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.

  • Associated Press14 days ago

    Shire: 2Q Earnings Snapshot

    The Dublin-based company said it had net income of $2.01 per share. Earnings, adjusted for one-time gains and costs, were $3.88 per share. The results beat Wall Street expectations. The average estimate ...

  • Shire profit edges higher ahead of Takeda sale
    Reuters14 days ago

    Shire profit edges higher ahead of Takeda sale

    Shire (SHP.L), the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations. Earlier on Tuesday, Takeda said its first-quarter operating profit had halved from a year ago, when it had booked gains from asset sales. It is buying Shire to broaden its drugs portfolio and plug a gap in its late-stage pipeline.

  • Company News For Jul 11, 2018
    Zackslast month

    Company News For Jul 11, 2018

    Companies In The News are: SHPG,SJM,XRX,PCAR

  • U.S. regulator backs Takeda's $62B acquisition of Shire
    American City Business Journalslast month

    U.S. regulator backs Takeda's $62B acquisition of Shire

    In a statement, Takeda said the Federal Trade Commission's approval "is another significant milestone" for the $62 billion deal.

  • Japan's Takeda gains U.S. approval for $62 billion Shire buy
    Reuterslast month

    Japan's Takeda gains U.S. approval for $62 billion Shire buy

    Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion (46.9 billion pounds) acquisition of London-listed Shire Plc (SHP.L), taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.

  • Japan's Takeda gains U.S. approval for $62 billion Shire buy
    Reuterslast month

    Japan's Takeda gains U.S. approval for $62 billion Shire buy

    Takeda Pharmaceutical Co Ltd on Tuesday said it has received U.S. approval for its $62 billion acquisition of London-listed Shire Plc, taking the Japanese firm one step closer to its goal of becoming a global top 10 drugmaker. Takeda in a press release said it received unconditional clearance from the United States Federal Trade Commission. The Tokyo-listed firm is still awaiting approval from regulators in China, the European Union and elsewhere, as well from shareholders of both parties.

  • Is Shire (SHPG) a Great Stock for Value Investors?
    Zackslast month

    Is Shire (SHPG) a Great Stock for Value Investors?

    Let's put Shire (SHPG) stock into this equation and find out if it is a good choice for value-oriented investors right now.

  • New Takeda HQ Flaunts Global Ambition Alongside Japan Roots
    Bloomberglast month

    New Takeda HQ Flaunts Global Ambition Alongside Japan Roots

    Embedded in the sleek metallic and cypress interior of Takeda Pharmaceutical Co.’s new global headquarters in Tokyo are stylized Japanese characters for words like life, water and light. Melding futuristic design with traditional Japanese elements highlights the balancing act facing Chief Executive Officer Christophe Weber: showing he can honor the 237-year-old drugmaker’s Japanese heritage as he tries to complete the biggest deal in Takeda’s history -- the $62 billion takeover of Shire Plc. “He’s very quick to say they’re still a Japanese company, but at the same time making a point to say they’re not Japanese because they have a very international, global executive team,” said John W. Carlson, chair of the health-care committee at the American Chamber of Commerce in Japan.

  • Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour
    Reuters2 months ago

    Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour

    A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion (47.36 billion pounds) acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favour, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

  • Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
    Reuters2 months ago

    Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor

    A group of Takeda Pharmaceutical Co Ltd shareholders, who are trying to build support to block the $62 billion acquisition of London-listed Shire Plc (SHP.L), failed to get a proposal passed at the drugmaker's annual general meeting (AGM) on Thursday. The proposal - to require advance shareholder approval for large acquisitions - received about 10 percent of votes in favor, the company confirmed to Reuters, casting doubt on the group's ability to gather enough support to scupper the Shire deal. The Shire deal would turn Takeda into one of the world's largest drugmakers but the group says it would require taking on too much financial risk.

  • FDA approves $1.2B plasma manufacturing center near Covington
    American City Business Journals2 months ago

    FDA approves $1.2B plasma manufacturing center near Covington

    An Irish company has received initial FDA approval for its $1.2 billion plasma manufacturing facility near Covington to produce an immunodeficiency treatment.

  • Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population
    Zacks2 months ago

    Shire (SHPG) HAE Drug Gets FDA Nod for Pediatric Population

    Shire (SHPG) gains FDA approval for expanding the label of its hereditary angioedema (HAE) drug, Cinryze, to include its usage among pediatric patients aged six years and older.

  • Nike takes a dive, Spotify surges, Shire up slightly
    Yahoo Finance2 months ago

    Nike takes a dive, Spotify surges, Shire up slightly

    Nike, Spotify and Shire are the Yahoo Finance charts of the day.

  • 5 Biotech Stocks Under $10 Worthy of Investors' Attention
    Zacks2 months ago

    5 Biotech Stocks Under $10 Worthy of Investors' Attention

    Small biotech stocks are good bets with lower market cap as well as share price.